文献速递血栓与止血

胶原周转生物标志物作为评估艾美赛珠单抗聚乙二醇化重组人凝血因子VIII治疗A型血友病疗效的客观指标:一项随机对照试验的二次分析

Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
PubMed 文献 · J Thromb Haemost · 2023-09-16

本研究为PROPEL随机对照试验的二次分析,纳入98例接受药代动力学指导预防治疗的A型血友病患者,目标凝血因子VIII谷浓度为1-3 IU/dL或8-12 IU/dL。结果显示,基底膜、间质和软骨相关胶原重塑标志物在治疗后3-6个月出现下降或上升,提示药代动力学指导的预防治疗可改善关节重塑。作者认为这些胶原重塑标志物值得进一步探索,以指导治疗改善血友病性关节病。

要点

  • 药代动力学指导的预防治疗可使基底膜和间质胶原重塑标志物在3个月后下降。
  • 软骨代谢相关标志物PRO-C2在6个月后上升,两个谷浓度组均如此。
  • 既往按需治疗患者中,不同谷浓度组间C3M和C4M变化有差异。

核心结论

  • 药代动力学指导的预防治疗可改善基底膜、间质基质和软骨特异性胶原重塑标志物所反映的关节状况。
  • 这些胶原重塑标志物值得进一步探索,作为指导治疗以改善血友病性关节病的生物标志物。

研究设计与样本

  • PROPEL研究(NCT0285960)的二次分析,纳入98例接受药代动力学指导预防治疗的A型血友病患者,目标凝血因子VIII谷浓度为1-3 IU/dL或8-12 IU/dL。
  • 在基线及第3、6、9、12个月分析血清胶原重塑产物水平。

主要发现

  • 基底膜代谢相关4型胶原重塑产物(C4M和PRO-C4)在3个月后所有时间点下降,1-3 IU/dL组最大下降25%(P=0.049,P<0.0001),8-12 IU/dL组最大下降25%(P=0.0002,P<0.0001)。
  • 间质组织代谢相关3型(C3M)和5型(PRO-C5)胶原重塑产物在3个月后下降,1-3 IU/dL组最大下降19%(P=0.0001,P=0.009),8-12 IU/dL组最大下降23%(P=0.0002,P=0.001)。
  • 软骨代谢相关2型胶原产物(PRO-C2,非C2M)在6个月后两个谷浓度组均上升至多12%(P=0.01,P=0.005)。
  • 按既往治疗分层,既往按需治疗患者中不同谷浓度组间C3M(P=0.03)和C4M(P=0.02)水平变化有差异,而既往预防治疗患者中未观察到差异。

关键数值与推荐

  • 目标凝血因子VIII谷浓度:1-3 IU/dL或8-12 IU/dL。
  • C4M和PRO-C4在1-3 IU/dL组最大下降25%(P=0.049,P<0.0001),在8-12 IU/dL组最大下降25%(P=0.0002,P<0.0001)。
  • C3M和PRO-C5在1-3 IU/dL组最大下降19%(P=0.0001,P=0.009),在8-12 IU/dL组最大下降23%(P=0.0002,P=0.001)。
  • PRO-C2在6个月后两个谷浓度组均上升至多12%(P=0.01,P=0.005)。
  • 既往按需治疗患者中,不同谷浓度组间C3M变化P=0.03,C4M变化P=0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些胶原重塑标志物值得进一步探索作为指导治疗改善血友病性关节病的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with hemophilia who have recurrent hemarthroses develop hemophilic arthropathy (HA). Regular prophylaxis with factor (F) VIII (FVIII) can reduce HA, but there is a need for objective outcome measures to evaluate treatment efficacy. OBJECTIVES: Evaluate and assess collagen turnover biomarkers in patients with hemophilia A to determine the efficacy of rurioctocog alfa pegol treatment and understand their potential as tools for guiding treatment decisions and monitoring outcomes. METHODS: Joint remodeling was assessed by analyzing serum levels of collagen remodeling products at baseline and months 3, 6, 9, and 12 in a 98 patient subset receiving pharmacokinetics-guided prophylaxis with rurioctocog alfa pegol, targeting FVIII trough levels of 1 to 3 International Units (IU)/dL or 8 to 12 IU/dL (PROPEL study, NCT0285960). RESULTS: Basement membrane metabolism-related type 4 collagen remodeling products (C4M and PRO-C4) decreased after 3 months at all time points by up to 25% at 1 to 3 IU/dL (P = .049, P < .0001) and 8 to 12 IU/dL FVIII trough levels (P = .0002, P < .0001). Interstitial tissue metabolism-related type 3 (C3M) and 5 (PRO-C5) collagen remodeling products decreased after 3 months, by up to 19% at 1 to 3 IU/dL FVIII trough level (P = .0001, P = .009) and 23% at 8 to 12 IU/dL FVIII trough level (P = .0002, P = .001). An increase of up to 12% was seen for cartilage metabolism-related type 2 collagen product (PRO-C2, not C2M) after 6 months at both trough levels (P = .01, P = .005). When stratified by prior treatment, changes in C3M (P = .03) and C4M (P = .02) levels were observed between trough levels for prior on-demand treatment but not for prophylaxis prior to study entry. CONCLUSION: Joint improvement measured by collagen remodeling biomarkers specific to the basement membrane, interstitial matrix, and cartilage was seen with pharmacokinetics-guided prophylaxis. These collagen remodeling biomarkers warrant further exploration as biomarkers to guide treatment toward improvement in HA.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Manon-Jensen T, Tangada S, Bager C, et al. Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial. J Thromb Haemost. 2023. PMID: 37717853. doi:10.1016/j.jtha.2023.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。